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Clarifying Endothelin Type B Receptor Function
David M. Pollock, Markus P. Schneider
Endothelin (ET) receptors have become the targets forthe treatment of a variety of cardiovascular disordersand a mixed ET type A (ETA)/ET type B (ETB)
receptor antagonist, bosentan, is currently being used to effec-
tively treat pulmonary hypertension. An ongoing debate has
revolved around the question of whether selective ETA receptor
blockade would be preferable to using the mixed antagonist. The
functional role of ET-1 is complicated by the opposing actions of
the ETA and ETB receptor in the vasculature, as well as the
kidney. ETB receptor function is further complicated by the
presence of vasoconstrictor ETB receptors on vascular smooth
muscle in some vascular beds, whereas ETB receptors on
endothelium and renal tubules have vasodilator and natriuretic
activities. ETB receptors also serve to clear ET-1 from the
circulation and, thus, minimize vasoconstrictor activity. Despite
the well-recognized effects of ETB receptors to oppose ETA-
mediated actions, it is not clear whether blocking both ETA and
ETB receptors at the same time is detrimental or advantageous
compared with selective ETA blockade. Indeed, ETA selective
antagonists are also expected to soon receive approval for
treatment of pulmonary hypertension. Although this may indi-
cate that both strategies work in pulmonary hypertension, the
pros and cons of selective versus mixed antagonists are much
less clear in arterial hypertension and heart and kidney failure.
Previous studies have shown that pharmacological blockade
or genetic deficiency of ETB receptors results in salt-sensitive
hypertension in rats.1,2 More recent studies have now provided
information on the location(s) of the ETB receptors responsible
for this effect. Ahn et al3 demonstrated salt-sensitive hyperten-
sion in mice where ET-1 expression was selectively knocked out
in the renal collecting duct. It was not clear, however, whether
ET-1 originating from the collecting duct acts on ETB receptors
of vascular elements within the renal medulla or in an autocrine
fashion on ETB receptors of collecting duct cells. In the current
issue of Hypertension, Bagnall et al4 report that selective
deletion of the ETB receptor from endothelial cells in mice has
no affect on blood pressure or salt sensitivity despite reduced
endothelial-dependent relaxation. The authors conclude that
ET-1 more likely acts in an autocrine fashion on collecting duct
cells, as opposed to activating endothelial ETB receptors on vasa
recta, which could facilitate sodium excretion through an in-
crease in medullary perfusion. This conclusion is further sup-
ported by reports that ETB receptors inhibit electrolyte reabsorp-
tion in vitro.5–7 Strictly speaking, a role for increased medullary
perfusion in the renal response to a high-salt diet mediated by the
ETB receptor cannot be completely ruled out yet. It is conceiv-
able that activation of ETB receptors on tubular cells causes vasa
recta to dilate through a “tubulovascular crosstalk” mechanism
similar to that described previously for buffering angiotensin
II–mediated vasoconstriction in the renal medulla and mediated
by NO.8 Although some questions do remain about the precise
mechanisms, the studies by Bagnall et al,4 together with previous
results from other groups, indicate a major role for renal tubular
ETB receptors in mediating ET-1–induced natriuresis.3,4,7
In addition to giving new insight into the renal mechanisms,
the current study also seems to dramatically reduce the likeli-
hood of vascular endothelial ETB receptors mediating salt-
sensitive hypertension during systemic ETB receptor blockade.
Interestingly, previous cross-transplantation experiments in ETB
receptor–deficient rats showed that salt sensitivity in this model
depended on the deletion of extrarenal ETB receptors.9 This
raises the possibility that a yet-unidentified extrarenal ETB receptor
may have a protective effect against salt-sensitive hypertension,
in addition to the ETB receptor on renal tubular cells.
Although it has been assumed for quite some time that the
endothelial ETB receptor is responsible for clearing circulating
ET-1, the functional ramifications of this concept have been
difficult to discern with other models in rats, such as pharma-
cological ETB receptor blockade or ETB receptor deficiency.1,2
Endothelial-specific ETB knockout mice have elevated levels of
circulating ET-1, which provide even more definitive evidence
for a role of ETB receptors on endothelium in clearing ET-1 from
the circulation. However, it is now also important to realize that
the resulting elevations in circulating ET-1 do not account for the
hypertension produced by pharmacological or genetic disruption
of the ETB receptor as documented previously.1,2 Several labo-
ratories have shown that hypertension produced by ETB receptor
blockade or high-salt intake in ETB receptor–deficient rats can
be blocked by ETA receptor antagonism.2,10,11 Although an
obvious argument is that a lack of ETB receptors displaces ET-1
to produce greater ETA receptor–dependent vasoconstriction,
this cannot account for the hypertension in these models given
these new findings. Just because ETA receptor blockade reduces
blood pressure in a model of hypertension does not signify that
the hypertension was produced by increased ETA receptor activa-
tion. It is also not clear how a shift of ET-1 from the ETB to the
ETA receptor could explain the salt dependence of these models.
Again, these new results favor a renal mechanism for the
salt-sensitive hypertension observed with ETB receptor blockade
or genetic deficiency of ETB receptors.
Although this study represents an important advance in our
understanding of how ET-1 controls blood pressure, there are a
number of questions about ETB receptor function that remain. It
should be noted that control mice in the current study were salt
sensitive, and so it will be important to establish that a lack of
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endothelial ETB receptors does not result in salt-dependent
hypertension in mice with a salt-resistant genetic background.
Another issue that no one has yet addressed is whether gastro-
intestinal absorption of salt is altered in animals lacking ETB
receptor function. ET-3, which selectively acts on ETB receptors,
has been shown previously to inhibit intestinal sodium reabsorp-
tion in dogs.12 The precise location of the ETB receptor respon-
sible for this effect can now be further investigated with this new
model or other tissue-specific models. Finally, there is emerging
evidence for ETB receptor influence within the sympathetic
nervous system that may participate in short-term blood pressure
control.13
Throughout the literature, there are many references to the
phenomenon known as “endothelial dysfunction.” It is quite
commonly referred to as a reduced vasodilator response to
acetylcholine administration, and so it is clear that we must now
include reduced ETB receptor function as one possible cause of
the dysfunction. Even more intriguing, reduced endothelial-
dependent vasodilation in endothelial cell ETB receptor knockout
mice does not translate into hypertension. These results add
important new information to the ongoing debate of whether
endothelial dysfunction is a cause or a consequence of hyper-
tension. Similarly, vascular overexpression of ET-1 in mice has
been shown to lead to endothelial dysfunction in the absence of
hypertension.14 Whether the absence of hypertension is specific
to the endothelial dysfunction induced by increased expression
of ET-1 or deletion of endothelial ETB receptors remains to be
determined. It will also be important to investigate what changes
in ETA receptor activity, if any, occur within the vascular system
when the ETB receptor is absent from the endothelium.
In summary, the work of Bagnall et al4 represents an impor-
tant advance in the understanding of how ET-1 controls blood
pressure and the response to salt and provides a valuable new
tool for exploring ETB receptor function. Because so much focus
has been on the negative effects of ETA receptor activation in
cardiovascular disease, function of the ETB receptor on the
endothelium has been a relatively underinvestigated aspect of
the ET system. Although many questions remain, the work from
this group and others, including results with the collecting
duct-specific knockout mice, clearly establish an important role
for renal epithelial ETB receptors in regulating salt excretion.
This study should provide an impetus for more focus on ETB
receptor function in control of vascular function and also
represents another important piece of the puzzle that will
eventually answer the question as to when and where ETB
receptor blockade may be helpful or harmful.
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